Results 151 to 160 of about 102,886 (302)

Ocular manifestations of graft-versus-host disease: 10 years’ experience

Clinical Ophthalmology, 2015
Xihui Lin, Harrison Dwight Cavanagh Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA Purpose: To evaluate the ocular presentation, treatment, and clinical course of graft-versus-host disease (GVHD).
Lin X, Cavanagh HD
doaj  

The integration of the British Pharmacological Society's prescription safety assessment into the WHO 6‐step model of rational pharmacotherapy in a Turkish medical school

British Journal of Clinical Pharmacology, EarlyView.
Aims At Koç University School of Medicine, a one‐week rational pharmacotherapy (RPHM) programme, modelled after WHO 6‐step, has been introduced in the fourth‐year curriculum to improve prescription skills. For efficient problem‐based learning (PBL) sessions on a prespecified topic, students need to brush up on basic pharmacology knowledge, so we ...
Sinem Ezgi Gülmez, Gülnihal Özcan, Hakan S. Orer   +2 more
wiley   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Lipidomic dataset of optic nerves from the silicone oil-induced ocular hypertension mouse model. [PDF]

Data Brief
Hao Z, Li W, Moceri I, Ma R, Holden D, Liu Y, Hong Y, Bhattacharya SK, Lee RK.   +8 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects

British Journal of Clinical Pharmacology, EarlyView.
Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto, Gabriël E. Jacobs, Joost C. van Mechelen, Laura G. J. M. Borghans, Johan G. C. van Hasselt, Linda B. S. Aulin   +5 more
wiley   +1 more source

Twelve-Month Outcomes of Standalone Travoprost Intracameral Implant in Glaucoma or Ocular Hypertension. [PDF]

Life (Basel)
Teymoorian S, Kaur J, Hornbeak DM, Barr E.   +3 more
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

The clinical characteristics and risk factors of steroid-induced ocular hypertension following pars plana vitrectomy. [PDF]

PLoS One
Jiang S, Yang H, Chen T, Ji Z, Yan X.
europepmc   +1 more source

Impact of empiric potassium supplementation on mortality, sudden cardiac arrest and stroke in furosemide initiators

British Journal of Clinical Pharmacology, EarlyView.
Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen, Sean Hennessy, Colleen M. Brensinger, Warren B. Bilker, Laura M. Dember, Todd A. Miano, Tat‐Thang Vo, Allison W. Willis, Charles E. Leonard   +8 more
wiley   +1 more source

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T. Tsuyuki, S. Rod Rassekh, Lesley G. Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C. Carleton, Geoffrey D. E. Cuvelier, Victor A. Lewis, Colin J. D. Ross, Alexandra P. Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D. Blydt‐Hansen, Brad L. Urquhart, The Applying Biomarkers to Minimize Long‐Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group, Tom Blydt‐Hansen, Bruce C. Carleton, Geoff D. E. Cuvelier, Sunil Desai, Prasad Devarajan, Conrad Fernandez, Adam Fleming, Paul Gibson, Caroline Laverdiere, Victor Lewis, Mary L. McBride, Bruno Michon, Shahrad Rod Rassekh, Colin J. D. Ross, Christine Sabapathy, Kirk R. Schultz, Michael Zappitelli, Alexandra Zorzi   +37 more
wiley   +1 more source